Macquarie Stem Cells has provided this information to educate the public based on peer reviewed, published scientific and medical documents. We don’t aim to encourage consumers to seek out such treatments prior to an assessment by a health professional to determine your suitability for treatment. This is obtained directly from The Lancet Literature. This article was funded by Arthritis Research UK, the National Institute for Health Research Biomedical Research Centre, and the Royal College of Surgeons (England). We aim to provide you with an unbiased range of treatments that are available aside from biological therapy, this is discussed in ‘supporting information>other-options’ page on our website.
Published: The Lancet – 2017
This new study has left medical professionals in a position where they will need to reconsider patient referrals related to shoulder arthroscopies. This issue affects surgeons all over Australia, unfortunately performing arthroscopies can be their main line of work, their bread and butter. But does it help the patient?
“Just recently, a new study has been published by the Lancet. This study has observed multiple centres, utilising randomised, placebo-controlled trials. There were 32 hospitals participating with a total of 51 surgeons. The study took on participants who had shoulder pain (subacromial) for at least 3 months.” (Beard et al., 2017)
“At 6 months, data for the Oxford Shoulder Score were available for 90 patients assigned to decompression, 94 to arthroscopy, and 90 to no treatment. Mean improvements via questionnaires did not differ between the two surgical groups at 6 months. However, both of the surgery groups presented greater improvements as opposed to the no treatment group. The conclusion for this study indicated any improvements may have been due to either placebo, or the efforts patients placed in post-operative physiotherapy.” (Beard et al., 2017)
“These findings question the value of this operation.This should be communicated to patients during the treatment decision-making process.” (Beard et al., 2017)
Now, orthopaedic surgeons need to deal with the struggle of justifying such an expensive procedure. Incidentally, this is not the first time this sort of publication has been published. Just recently, we posted a blog entry about the cost benefit analysis of joint arthroscopies. The publication can be found here.
As stated by Dr. J. Coleman “many orthopods are already adapting, and knee arthroscopy rates are waning. Though, last weekend’s Australian Financial Review indicated that the Australian Orthopaedic Association is in no mood to encourage the decline.”
Medicine is constantly changing, it is time for our governing bodies to start adapting. We need this to happen sooner, rather than later.
REF :Beard, D., Rees, J., Cook, J., Rombach, I., Cooper, C., Merritt, N., Shirkey, B., Donovan, J., Gwilym, S., Savulescu, J., Moser, J., Gray, A., Jepson, M., Tracey, I., Judge, A., Wartolowska, K., Carr, A., Ahrens, P., Baldwick, C., Brinsden, M., Brownlow, H., Burton, D., Butt, M., Carr, A., Charalambous, C., Conboy, V., Dennell, L., Donaldson, O., Drew, S., Dwyer, A., Gidden, D., Hallam, P., Kalogrianitis, S., Kelly, C., Kulkarni, R., Matthews, T., McBirnie, J., Patel, V., Peach, C., Roberts, C., Robinson, D., Rosell, P., Rossouw, D., Senior, C., Singh, B., Sjolin, S., Taylor, G., Venkateswaran, B. and Woods, D. (2017). Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. The Lancet.
Tags: Macquarie Stem Cells, Dr. Bright, Osteoarthritis Treatment, Dr. Ralph Bright, Joint Arthroscopes, Arthroscopy failure, alternatives for arthritis, alternative for arthroscopy
Remember, any surgical or invasive procedure carries risks. Before proceeding, you should seek a second opinion from an appropriately qualified health practitioner.